GERMANTOWN, Md.–(BUSINESS WIRE)–Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology
company focused on the development and commercialization of a long-term,
implantable continuous glucose monitoring (CGM) system for people with
diabetes, today announced the company plans to participate in the
upcoming Raymond James Life Sciences and MedTech Conference in New York,
NY.
Management is scheduled to present Tuesday, June 18, 2019 at 4:10pm ET.
Interested parties may access a live and recorded webcast of the
presentation on the “Investor Relations” section of the company’s
website at www.senseonics.com.
About Senseonics
Senseonics Holdings, Inc. is a medical technology company focused on the
design, development and commercialization of transformational glucose
monitoring products designed to help people with diabetes confidently
live their lives with ease. Senseonics’ CGM systems, Eversense®
and Eversense® XL, include a small sensor inserted completely
under the skin that communicates with a smart transmitter worn over the
sensor. The glucose data are automatically sent every 5 minutes to a
mobile app on the user’s smartphone.
Contacts
Senseonics Investor Relations Contact:
Lynn Lewis or Philip
Taylor
Investor Relations
415-937-5406
[email protected]
